SEARCH
= Registered usersComparing 5-ARIs in benign prostatic hyperplasia
20 Sep 2011
Finasteride and dutasteride appear to have similar efficacy in benign prostatic hyperplasia (BPH) over 12 months, a head-to-head study has shown. Dr Rees, in this review of the study, comments: 'Finasteride is now off patent and the generic version is therefore considerably cheaper to prescribe than dutasteride. Studies such as COMBAT have shown the prolonged benefit of 5-ARIs at least up to five years, and thus the major limitation of this study is its relatively short duration of 12 months. 5-ARIs should be considered to be long-term therapy, and thus longer follow-up of these two arms would be of even greater interest. Long-term studies of combination therapy with finasteride and tamsulosin versus dutasteride and tamsulosin would also be of great clinical interest.'
This article can be accessed only if you are a paid-up subscriber to The Practitioner.
To subscribe contact: thepractitioner@servicehelpline.co.uk
Overseas subscription
Individual: £138Institutional: £138
Overseas: +44 (0)1795 418 670
Subscription enquiry: thepractitioner@servicehelpline.co.uk
UK subscription
Individual: £85Institutional: £85
UK: 0844 815 5934
Subscription enquiry: thepractitioner@servicehelpline.co.uk